Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Sotorasib (Lumakras) is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, who have received at least one prior systemic therapy.
• A single systematic review/meta-analysis focused on the efficacy and safety of KRAS^G12C inhibitors, specifically sotorasib and adagrasib, in treating solid tumors.
• The meta-analysis involved 18 studies with a total of 1,224 patients having KRAS^G12C-mutated solid tumors.
• Results from this analysis showed an objective response rate (ORR) of 31%, disease control rate (DCR) of 86%, and incidence rate of grade ≥3 adverse events (AEs) at 29% among these patients treated with sotorasib.
• Patients harboring a co-mutation in KEAP1 had worse ORRs compared to those without it when treated with sotorasib, indicating that genetic profiling could be crucial in identifying patient subgroups likely to benefit most from such targeted treatments.
• While direct comparison data between Lumakras (sotorasib), adagrasib, and other treatments were not provided within this study; based on available information, Lumakras provides meaningful clinical benefits along with manageable side effects for patients suffering from NSCLC carrying the specific mutation.